PFE - Pfizer Inc.
43.20 -0.06 (-0.14%)
After hours: 6:23PM EDT
| Previous Close | 43.51 |
| Open | 43.42 |
| Bid | 0.00 x 21500 |
| Ask | 0.00 x 1800 |
| Day's Range | 42.99 - 43.68 |
| 52 Week Range | 33.20 - 43.68 |
| Volume | 22,564,634 |
| Avg. Volume | 19,596,235 |
| Market Cap | 253.595B |
| Beta | 0.87 |
| PE Ratio (TTM) | 11.55 |
| EPS (TTM) | N/A |
| Earnings Date | N/A |
| Forward Dividend & Yield | 1.36 (3.17%) |
| Ex-Dividend Date | 2018-08-02 |
| 1y Target Est | N/A |
- Market Realist•12 hours ago
Pharma Stocks: Pfizer’s Revenue Trend and 2018 Estimates
Pfizer reported a rise of 4% in its top line to ~$13.47 billion, including a 2% rise in operating revenue and a 2% favorable impact of foreign exchange, in the second quarter. Its net adjusted income rose to ~$4.8 billion in the second quarter, an 18.8% rise compared to ~$4.1 billion in the second quarter of 2017.
- Market Realist•15 hours ago
Pharma Stocks in Review: A Valuation Comparison
In this article, we’ll compare the valuations of Eli Lilly and Company (LLY), Pfizer (PFE), Merck & Co. (MRK), Allergan (AGN), and GlaxoSmithKline (GSK).
- MarketWatch•yesterday
Health care ETF surges toward record in a broad sector rally
The SPDR Health Care Select Sector ETF rose 0.7% toward a record high in afternoon trade Tuesday, with 55 of its 63 equity components gaining ground. Among the ETF's (XLV) members which are also Dow Jones Industrial Average components, Pfizer Inc.'s stock shot up 1.5%, putting it on track to close at the highest level since December 2001. Also, shares of Johnson & Johnson gained 0.6% toward an eight-month high, Merck & Co. Inc. tacked on 0.4% to sit just shy of its 17-year high reached last Thursday, and UnitedHealth Group Inc. slipped 0.1% and was 2.2% below its Sept. 6 record close of $269.65. The XLV's biggest gainer was Abiomed Inc.'s stock , which rallied 2.7%, while its biggest decliner was AbbVie Inc.'s stock , which shed 2.1% after California sued the company alleging the payment of illegal kickbacks. The XLV has rallied 11% over the past three months, while the Dow has tacked on 5.2%.
- Market Realist•yesterday
A Review of Pharma Stocks’ EPS Growth Rates
In this article, we’ll compare the EPS growth rates of pharmaceutical companies Eli Lilly and Company (LLY), Pfizer (PFE), Merck & Co. (MRK), Allergan (AGN), and GlaxoSmithKline (GSK).
Market Realist•yesterdayWatson Health Still the Key Driver for IBM’s AI Business
The growing demand for AI in the health industry has encouraged IBM (IBM) to target the health sector with its Watson Health technology. The company’s increasing presence, particularly in oncology and not only in the United States but also in highly populated countries such as China and India, is also contributing to Watson Health’s growth.
- Market Realist•2 days ago
Exploring Pharmaceutical Stocks’ Revenue Growth Rates
In this article, we’ll compare the revenue growth rates of the pharmaceutical companies under review in this series: Eli Lilly and Company (LLY), Pfizer (PFE), Merck & Co. (MRK), Allergan (AGN), and GlaxoSmithKline (GSK).
- Zacks•2 days ago
Is the Options Market Predicting a Spike in Pfizer (PFE) Stock?
Investors need to pay close attention to Pfizer (PFE) stock based on the movements in the options market lately.
- Zacks•2 days ago
Can Pfizer (PFE) Bank on Bavencio for Long-Term Growth?
Pfizer's (PFE) latest anti-PD-L1 immunotherapy, Bavencio, is being touted as a significant long-term top-line driver for the company.
- Market Realist•2 days ago
A Look at the Dividends Paid by Pharma Stocks in 2018
In this article, we’ll discuss the details of the dividends paid by pharmaceutical stocks Eli Lilly and Company (LLY), Pfizer (PFE), Merck & Co. (MRK), Allergan (AGN), and GlaxoSmithKline (GSK).
Market Realist•2 days agoDelstrigo, Pifeltro, and Merck’s Antiviral Therapy Portfolio
In the second quarter, Merck’s (MRK) Zepatier and Isentress reported revenues of $113.0 million and $305.0 million, respectively, which represented an ~78.0% decline and 8.0% growth on a YoY (year-over-year) basis. In the first half, Zepatier and Isentress reported net revenues of $243.0 million and $586.0 million, respectively.
- InvestorPlace•2 days ago
Cronos Gets Bigger As It Partners With Ginkgo Bioworks
From the looks of Cronos Group, Inc. (NASDAQ:CRON) on the charts, the stock looked like it topped around $13 and is on the way down. On Sept. 4, Cronos announced a partnership with Ginkgo Bioworks. It will produce cultured cannabinoid, the active ingredient produced in cannabis plants.
- Zacks•2 days ago
Pfizer's Skin Disease Candidates Positive in Mid-Stage Study
Pfizer's (PFE) JAK inhibitor candidates -- PF-06651600 and PF-06700841 -- demonstrate improvements in moderate to severe alopecia areata patients in a phase II study.
- Market Realist•2 days ago
A Look at the Market Caps of the Pharma Stocks under Review
As we discussed earlier, a few of the pharmaceutical stocks that have surpassed the returns of the S&P 500 Index YTD (year-to-date) include Eli Lilly and Company (LLY), Pfizer (PFE), Merck & Co. (MRK), Allergan (AGN), and GlaxoSmithKline (GSK). Let’s take a look at the details of their market caps.
- Market Realist•2 days ago
How Pharmaceutical ETFs Have Performed in 2018
Pharmaceutical ETFs are securities that are publicly traded on stock markets designed for investors who don’t have the capacity to hold many stocks but are interested in diversification within the pharmaceutical sector.
- Market Realist•2 days ago
These Pharmaceutical Stocks Have Surpassed the S&P 500 in 2018
The US pharmaceutical sector is made up of players that include drug manufacturers, drug marketers, and biotechnology companies.
- American City Business Journals•2 days ago
This cancer-fighting biotech sped from startup to IPO filing in 10 months
The company has raised $420 million and its experimental off-the-shelf cell therapy against cancer is in the clinic. But two deaths have been attributed to its headlining drug.
- Market Realist•3 days ago
Keytruda Could Boost Merck’s Revenue Growth in 2018 and Beyond
On September 12, Merck (MRK) announced that the FDA accepted for review the company’s new supplemental Biologics License Application (or sBLA) for the label expansion of Keytruda. Merck seeks label expansion of Keytruda for approval as a monotherapy in the first-line setting. This treatment is intended for individuals with metastatic nonsquamous or squamous NSCLC (non-small cell lung cancer) with tumors expressing PD-L1 without EGFR or ALK genomic tumor abnormalities.
- Market Realist•5 days ago
Wall Street Analysts Are Mostly Positive on Merck in September
Merck (MRK) recently announced that its pivotal Phase 3 trial that evaluated Zerbaxa met its primary endpoint. Zerbaxa is an investigational antibiotic for the treatment of adult individuals with ventilated hospital-acquired bacteria pneumonia or ventilator-associated bacterial pneumonia (or VABP). Zerbaxa demonstrated non-inferiority compared to meropenem.
- Zacks•5 days ago
Pfizer (PFE) Outpaces Stock Market Gains: What You Should Know
Pfizer (PFE) closed at $42.97 in the latest trading session, marking a +0.34% move from the prior day.
- Market Realist•5 days ago
How Spark Therapeutics Is Positioned in 2018
Spark Therapeutics (ONCE) is a gene therapy company focused on developing one-time treatments that are life-altering for genetic disease patients. Spark Therapeutics has a licensing and commercialization agreement with Novartis (NVS) for its investigational voretigene neparvovec. Spark Therapeutics has two gene therapy product candidates in its pipeline: SPK-7001 and SPK-8011.
Zacks•5 days agoPharma Stock Roundup: AZN's Leukemia Drug Wins FDA Nod, MRK's Keytruda in Focus
Label expansion of Merck's (MRK) Keytruda and FDA approval of AstraZeneca's (AZN) leukemia drug grab headlines this week
- Zacks•5 days ago
Pharma/Biotech Stocks to Watch This Prostate Cancer Month
Here we highlight a few companies that are focused on developing treatments for prostate cancer.
- Zacks•6 days ago
Dow 30 Stock Roundup: Apple Unveils 3 New iPhones, Boeing Clinches $2.9B Deal
The index chalked up gains this week amid renewed hopes of trade talks between the United States and China.
- Motley Fool•6 days ago
A Brawl Is Brewing Between AbbVie and Gilead Sciences in Arthritis
AbbVie's upadacitinib and Gilead Sciences' filgotinib could be competing for rheumatoid arthritis market share in 2020.
Market Realist•6 days agoSangamo Therapeutics: The Promise of Zinc Fingers
Sangamo Therapeutics (SGMO) is focused on developing and commercializing novel genomic therapies. Its genome editing and gene regulation platform is based on the engineering of a type of transcription factors called zinc finger DNA binding proteins (or ZFP) that naturally occur in humans. Sangamo has entered into key collaborations with Kite Pharma, a subsidiary of Gilead Sciences (GILD) and Pfizer (PFE).
